Mixed results with drug delivery to prevent in-stent restenosis
This article was originally published in Clinica
Executive Summary
Low molecular-weight (LMW) heparin delivered via catheter after coronary stent implantation does not prevent subsequent restenosis, according to the largest trial to date of the treatment. However, a smaller Polish study claims the technique can cut restenosis rates by a half.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.